ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: A randomized phase 2 study Research Letter

   

Authors:	Strati, P.; Fanale, M. A.; Oki, Y.; Turturro, F.; Fayad, L. E.; Bartlett, N. L.; Gladstone, D. E.; Kasamon, Y. L.; Portlock, C. S.; Wilson, W. H.; Goy, A.; Younes, A.; Lee, H. J.
Title:	ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: A randomized phase 2 study
Journal Title:	Haematologica
Volume:	104
Issue:	2
ISSN:	0390-6078
Publisher:	Ferrata Storti Foundation
Date Published:	2019-02-01
Start Page:	e65
End Page:	e67
Language:	English
DOI:	10.3324/haematol.2018.199844
PUBMED:	30190343
PROVIDER:	scopus
PMCID:	PMC6355491
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060939152&doi=10.3324%2fhaematol.2018.199844&partnerID=40&md5=872bb19a8a2b8a59a8d26122e2494864
Notes:	Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/142621